PHARMASOLUTIONS
ActiveSummary
PHARMASOLUTIONS has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €181,088 and a net result of €70,854. Equity is growing by about 59% per year across the filed financial years. Its solvency ranks better than 91% of 22,536 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
11-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2023 to 2025net €70,854 ▲19.3%
Operating result €98,035, net result €70,854, both a record.
31-12
Financial
Equity above €150,000equity €181,088 ▲64.3%
A profit in every financial year since 2023 builds equity to €181,088.
11-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-12
Financial
Equity above €100,000equity €110,234 ▲117%
A profit in every financial year since 2023 builds equity to €110,234.
26-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.